Recent research have converged on the convergence of GLP|GIP|GCGR activator therapies and dopaminergic signaling. While GLP activators are commonly employed for addressing type 2 T2DM, their emerging impacts on reinforcement circuits, specifically influenced by DA pathways, are receiving signific